Nasus Pharma Announces Phase 2 Results From NS002 Shows Improvements In Early Absorption Compared To EpiPen; Pivotal Trial Planned For !4

Nasus Pharma Ltd. (NYSE: NSRX) announced positive Phase 2 results for its intranasal product NS002, showing significant improvements in early absorption compared to EpiPen, with a pivotal trial planned for Q4 2026. The company is also advancing its pipeline assets NS003 and NS004, targeting first-in-human studies in the second half of 2026. Nasus Pharma is well-funded for the upcoming pivotal study and potential NDA submission.